Novo Nordisk Pharma (Thailand) Ltd.
Pharmaceutical
- Enrico Cañal Bruland, General Manager (Thailand)
- Imre Krisztian Zsoldos, Finance & Operations Director
- Rebecca Kehberg Bendtsen, People & Organization Director
- Gurudutt Nayak, CMR Director
- Nattha Srisomwong,Legal, Compliance & Quality Director
- Ticha Chookham, Senior Sales Director - Diabetes
- Nattaporn Huajaikaew, Marketing Director - Diabetes
- Yuwadee Chiratiticharoen, Business Unit Director – Obesity
- Selina Christodoulakis, Director - Rare Disease & Patient Access
- Itthipon Lalitthamsiri, Director of Customer Engagement
98 Sathorn Square Office Tower Unit 2101-2105, 2112, 21st Floor, North Sathorn Road, Silom, Bangrak, Bangkok, 10500 Thailand
+66 2 237 9263
[email protected]
We have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. We make long-term investments in novel treatments and technologies, including curative stem cell based therapies, to continually advance the development of medical devices and digital health solutions. Providing treatment for five diseases.
1. Diabetes Type 1
2. Diabetes Type 2
3. Obesity
4. Haemophilia
5. Growth Disorders
Name:
Enrico Cañal Bruland
Position:
Vice President & General Manager (Thailand)
Contact information for member only.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com,
Facebook, Twitter, LinkedIn and YouTube.
